A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
Latest Information Update: 13 Dec 2023
At a glance
- Drugs Efprezimod alfa (Primary) ; Methotrexate; Tacrolimus; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors OncoImmune
- 30 Aug 2023 Primary endpoint has been met, (Open Label Expansion Arm Only: Grade III-IV Acute Graft-Versus-Host Disease (GVHD) Free Survival (AGFS), as per Results published in the Blood
- 30 Aug 2023 Results published in the Blood
- 23 Apr 2021 Planned End Date changed from 30 Apr 2021 to 5 May 2021.